Sign In

QOPI
ASCO QOPI

Report on evidence-based quality measures and receive performance scores via the Quality Oncology Practice Initiative (QOPI®).

Sign In

FDA Approves Pembrolizumab as Adjuvant Treatment For Non-Small Cell Lung Cancer

Oncology Practice Insider

Related

FDA Approves Dabrafenib With Trametinib For Pediatric Patients With Low-grade Glioma With a BRAF V600E Mutation
FDA Expands Early Breast Cancer Indication For Abemaciclib With Endocrine Therapy
FDA Grants Accelerated Approval to Pirtobrutinib For Relapsed or Refractory Mantle Cell Lymphoma
FDA Alerts

On January 26, 2023, the Food and Drug Administration (FDA) approved pembrolizumab (Keytruda, Merck) for adjuvant treatment following resection and platinum-based chemotherapy for stage IB (T2a ≥4 cm), II, or IIIA non-small cell lung cancer (NSCLC). Read more.